Registering a CAGR of 8.9% over the forecast period, the market value of Anti-Migraine Drugs is expected to reach US$ 12.1 billion in the year 2027.
A migraine is a frequent neurological illness that causes throbbing, pounding headaches that vary in intensity on one side of the brain. Tetracycline, an antibiotic that works by preventing bacteria from growing, can produce acute migraine headaches, as well as nausea, vomiting, diarrhoea, and a loss of appetite. Migraine medications are intended to lessen the severity of migraine headaches. Aura signs, such as flashing lights or zigzag lines, can occasionally precede migraine headaches. If your migraine with aura is accompanied by nausea and vomiting, you should take anti-nausea medication. Opioid-containing medications, such as oxycontin, Vicodin, Percocet, and others, prevent migraine central sensitization from reversing.
The drugs used to treat migraines are divided into two types: abortive and preventative. Preventive medications are used to reduce the number of migraine attacks whereas abortive meds are used to interrupt an existing migraine attack. The increased prevalence of migraines, rising healthcare expenditures, and rising awareness about anti-migraine pharmaceuticals are some of the reasons driving the Anti-Migraine Drugs Market growth between 2022 and 2027.
The report aspects discussed the profile of the top manufacturers of the global Anti-Migraine Drugs market. These aspects include financial status of major companies, trending advancements and entire market scenario. Growth of the report have examined Anti-Migraine Drugs Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.
Sept. 28, 2021-- FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine--
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.2
22 October 2019 - Lundbeck completes the acquisition of Alder BioPharmaceuticals - a company committed to transforming migraine treatment and prevention--
H. Lundbeck A/S (Lundbeck) today announced that it has successfully completed the acquisition of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) (“Alder”) a migraine-focused company based in Bothell, Washington, for an aggregate cash consideration of up to approximately USD 1.95 billion (DKK 13 billion) net of cash, on a fully diluted basis. The transaction, which was announced on 16 September 2019, significantly accelerates and strengthens the build of Lundbeck’s pipeline.
Market is segmented based on the type, applications, companies and regions.
By Type, it is segmented into
By Application, it is segmented into
Geographically, the Anti-Migraine Drugs market may be divided into North America, Europe, Asia-Pacific, South America, and the Rest of the World. Because to the rising prevalence of migraine and increasing use of anti-migraine and anti-nausea medications, North America held a strong market share of 40.5% in 2021 when compared to its peers. Migraine affects roughly 37 million men, women, and children in the United States, according to the American Migraine Association. A migraine sufferer can be found in one out of every four households.
Due to an increase in demand for better healthcare facilities, raising awareness about the effectiveness of anti-migraine drugs, untapped investment potential, and rising prevalence of migraine, Asia-Pacific is expected to be the fastest-growing region, with a CAGR of 6.2 percent over the forecast period of 2022-2027. Because of its fastest-growing pharmaceutical sector, China now dominates and is expected to continue to dominate the Asia-Pacific migraine treatment market during the projection period. Over the projected period, China's government's pharma policies and incentives aimed at reforming the pharmaceutical industry are expected to boost market growth.
The Anti-Migraine Drugs Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Anti-Migraine Drugs Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Report Attributes | Report Details |
Forecast Period 2022 to 2027 CAGR | CAGR of 8.9% over the forecast period (2022-2027) |
By Type |
|
By Application |
|
By Companies | Eli Lilly, Abbott Laboratories, Eisai, Allergan, Endo, GlaxoSmithKline, Impax Laboratories, Pfizer, AstraZeneca, Bayer, Johnson & Johnson, Merck, Teva, Amgen |
Regions Covered |
|
Countries Covered |
|
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2022 to 2027 |
Number of Pages | 166 |
Customization Available | Yes, the report can be customized as per your needs |
What is the growth rate of Anti-Migraine Drugs Market?
The Anti-Migraine Drugs Market is growing at a CAGR of 8.9% over the next 5 years.
Who are the key players in Anti-Migraine Drugs Market?
Eli Lilly, Abbott Laboratories, Eisai, Allergan, Endo, GlaxoSmithKline, Impax Laboratories, Pfizer, AstraZeneca, Bayer, Johnson & Johnson, Merck, Teva, Amgen
What are the significant types of Anti-Migraine Drugs Market?
Triptans, Ergots, Others
What are the major end-use applications of Anti-Migraine Drugs Market?
Women, Men
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.